



BACKGROUND

In 2023, our team dedicated over 1,600 hours to pre-site activities, such as completing feasibility questionnaires. These forms contain redundant site-specific information, requiring significant effort and time from the team. Some questions were outside our ability to answer or did not directly impact our capacity to accrue patients. This inefficiency highlights an opportunity to streamline the process to reduce redundancy and refocus valuable time on tasks that more effectively support trial activation and patient care.

GOALS

Create efficiency by eliminating redundant work on sponsor feasibility questionnaires.

SOLUTIONS & METHODS

In 2023, we initiated the development of a comprehensive site information packet to address the redundancy and inefficiencies of sponsor feasibility questionnaires. Using our existing sponsor questionnaire and reviewing recent sponsor feasibility forms, we created a packet that consolidated frequently asked questions about our site, along with a source packet detailing where to locate specific information. Additionally, we conducted a total overhaul to our sponsor questionnaire focusing on key information required for regulatory submissions.

We implemented a streamlined process: when considering a study, we send sponsors a standard email with both the information packet and our questionnaire. This standard communication outlines our policy of not filling out feasibility questionnaires, aiming to expedite site selection and activation. If sponsors have additional questions not addressed in our packet, we request they return these via email. We also clarify that we do not provide specific patient population numbers, as these figures do not impact our ability to enroll patients. Instead, we offer broad disease category numbers and an anticipated enrollment (when requested).

OUTCOMES

In 2024, we saw a 40.5% reduction in time spent on pre-pending activities by our Research Coordinators. Overall, this approach was well-received by our pharmaceutical sponsors and CROs. We have reduced time spent on questionnaires and allowed our team to focus on tasks that directly support trial activation.

LESSONS LEARNED & FUTURE DIRECTIONS

This change in process has ultimately been a positive one for our teams. We will continue to monitor time spent on pre-pending activities and evaluate our information packet and questionnaire quarterly for improvements/updates. We hope to continue to see a decrease in time spent on pre-pending activities.

Cleveland Clinic
Taussig Cancer Institute

[Cleveland Clinic Taussig Cancer Center Site Information Packet](#)

The purpose of the Site Information Packet is to provide sponsors with one comprehensive document which outlines the Taussig Cancer Center's Main Campus clinical trial capabilities and qualifications. Our goal is to activate trials within 90 days. The below information in conjunction with the Industry Sponsored Clinical Trial Questionnaire aids us in this goal.

Table of Contents	
1.0 Treatment Site Information.....	2
1.1 Cleveland Clinic Taussig Cancer Center Site Capabilities.....	
1.2 Case Comprehensive Cancer Center (CCCC).....	
1.3 Treatment Locations.....	
1.4 Facilities.....	
2.0 Regulatory Processes.....	3
3.0 Training.....	4
4.0 Budget & Contract.....	4
5.0 Monitoring Information.....	5
6.0 Pharmacy Information.....	5
6.1 Investigational Product (IP) Inventory.....	
6.2 IP Preparation.....	
6.3 Equipment.....	
7.0 Clinical Research Services Lab Information.....	6
7.1 Laboratory Equipment.....	
7.2 Laboratory Capabilities.....	
8.0 Cellular Therapy Laboratory.....	7
9.0 Radiology Information.....	8
10.0 Radiation Oncology.....	8
11.0 Source Documents.....	8
11.1 Source Document Collection.....	
11.2 Electronic Source Documentation.....	
11.3 Archiving.....	
Appendix I: Regional Sites.....	11
Appendix II: Case Comprehensive Cancer Center.....	12

Version 1.3 10/04/2024 Page 1 of 14